Sustained complete response of hepatocellular carcinoma with portal vein tumor thrombus following discontinuation of sorafenib: A case report

Shiozawa,Kazue; Watanabe,Manabu; Ikehara,Takashi; Matsukiyo,Yasushi; Kogame,Michio; Kanayama,Masahiro; Matsui,Teppei; Kikuchi,Yoshinori; Ishii,Koji; Igarashi,Yoshinori; Sumino,Yasukiyo

doi:10.3892/ol.2013.1664

2014-January Volume 7 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

2014-January Volume 7 Issue 1

Full Size Image

Case Report

Sustained complete response of hepatocellular carcinoma with portal vein tumor thrombus following discontinuation of sorafenib: A case report

Authors:
- Kazue Shiozawa
- Manabu Watanabe
- Takashi Ikehara
- Yasushi Matsukiyo
- Michio Kogame
- Masahiro Kanayama
- Teppei Matsui
- Yoshinori Kikuchi
- Koji Ishii
- Yoshinori Igarashi
- Yasukiyo Sumino
View Affiliations / Copyright

Affiliations: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Medical Center, Omori Hospital, Ota‑ku, Tokyo 143‑8541, Japan
Pages: 50-52
|
Published online on: November 7, 2013

https://doi.org/10.3892/ol.2013.1664
Expand metrics +

Abstract

Hepatocellular carcinoma (HCC) is the third most common cause of cancer‑associated mortality worldwide. No effective treatment has been established for unresectable advanced HCC, and the prognosis is poor. Sorafenib is an oral multi‑targeted tyrosine kinase inhibitor for unresectable advanced HCC that significantly improves progression‑free and overall survival. However, in the two large phase III clinical trials (the SHARP and Asia‑Pacific trials), no cases of complete response (CR) were reported. The present study reports the case of a 68‑year‑old male with hepatitis C virus‑related cirrhosis and multiple recurrent HCCs, with a tumor thrombus of the third portal vein following resection. The patient received 400 mg once daily (half the standard dose) of sorafenib for two years and achieved a CR. At the most recent follow‑up examination at one year after the cessation of treatment, the patient was observed to be in remission without clinical or imaging evidence of disease recurrence.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2	Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
3	Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar
4	Inuzuka T, Nishikawa H, Sekikawa A, et al: Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report. Oncology. 81(Suppl 1): S152–S157. 2011. View Article : Google Scholar : PubMed/NCBI
5	Chan A and Tan EH: How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? Support Care Cancer. 19:1667–1674. 2011. View Article : Google Scholar
6	Edeline J, Boucher E, Rolland Y, et al: Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 118:147–156. 2012. View Article : Google Scholar
7	Wilhelms S, Carter C, Lynch M, et al: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 5:835–844. 2006. View Article : Google Scholar : PubMed/NCBI
8	Shiozawa K, Watanabe M, Kikuchi Y, Kudo T, Maruyama K and Sumino Y: Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study. World J Gastroenterol. 18:5753–5758. 2012. View Article : Google Scholar
9	So BJ, Bekaii-Saab T, Bloomston MA and Patel T: Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report. J Hematol Oncol. 1:182008. View Article : Google Scholar
10	Wang SX, Byrnes A, Verma S, Pancoast JR and Rixe O: Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report. Target Oncol. 5:59–63. 2010. View Article : Google Scholar
11	Kudo M and Ueshima K: Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. Oncology. 78:154–166. 2010. View Article : Google Scholar
12	Sacco R, Bargellini I, Gianluigi G, et al: Complete response for advanced liver cancer during sorafenib therapy: case report. BMC Gastroenterol. 11:42011. View Article : Google Scholar : PubMed/NCBI
13	Li Q, Xu B, Fu L and Hao XS: Correlation of four vascular specific growth factors with carcinogenesis and portal vein tumor thrombus formation in human hepatocellular carcinoma. J Exp Clin Cancer Res. 25:403–409. 2006.
14	Johannsen M, Flörcken A, Bex A, et al: Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicenter, retrospective analysis. Eur Urol. 55:1430–1438. 2009. View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Sustained complete response of hepatocellular carcinoma with portal vein tumor thrombus following discontinuation of sorafenib: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles